Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 92, Issue 5, Pages 563-566Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2012.140
Keywords
-
Categories
Funding
- National Cancer Institute [CA 36401, CA 21765]
- NIH/NIGMS Pharmacogenomics Research Network [U01 GM92666, U01 HL105198]
- American Lebanese Syrian Associated Charities
Ask authors/readers for more resources
Advances in pharmacogenetic testing will expand the number of clinically important pharmacogenetic variants. Communication and interpretation of these test results are critical steps in implementation of pharmacogenetics into the clinic. Computational tools that integrate directly into the electronic medical record (EMR) are needed to translate the growing number of genetic variants into interpretive consultations to facilitate gene-based drug prescribing. Herein, we describe processes for incorporating pharmacogenetic tests and interpretations into the EMR for clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available